JNJ EVP Schmid sells 1,322 shares at $245.66

Johnson & Johnson EVP Timothy Schmid reported an open-market sale of 1,322 shares of common stock at $245.66 per share on February 20, 2026.

Rhea-AI Filing Summary

Johnson & Johnson EVP Timothy Schmid reported an open-market sale of 1,322 shares of common stock at $245.66 per share on February 20, 2026. After this transaction, he directly held 25,447 shares of Johnson & Johnson.

He also reported indirect holdings of 46 shares through an ESOP under the Johnson & Johnson Savings Plan and 745 shares through a 401(k), both based on the plan’s most recent reporting date of January 31, 2026.

Insider Trade Summary

Net Seller: 1,322 shares

Net Sell 3 txns

Insider Schmid Timothy

Role EVP, WW Chair, MedTech

Sold 1,322 shs ($325K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,322	$245.66	$325K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 25,447 shares (Direct); Common Stock — 46 shares (Indirect, By ESOP); Common Stock — 745 shares (Indirect, By 401k)

Footnotes (2)

1. F1. Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026).
2. F2. Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Johnson & Johnson (JNJ) report for Timothy Schmid?

Johnson & Johnson reported that EVP Timothy Schmid executed an open-market sale of 1,322 shares of common stock on February 20, 2026, at $245.66 per share. This Form 4 filing reflects a single reported sell transaction for that date.

How many Johnson & Johnson (JNJ) shares did Timothy Schmid own after the sale?

After the reported sale, Timothy Schmid directly held 25,447 shares of Johnson & Johnson common stock. The Form 4 also discloses additional indirect holdings through an ESOP and a 401(k) plan, which are reported separately from his direct ownership position.

What was the sale price for Timothy Schmid’s Johnson & Johnson (JNJ) shares?

The reported open-market sale by Timothy Schmid was executed at a price of $245.66 per Johnson & Johnson share. This per-share price applies to the 1,322 common shares sold in the transaction disclosed for February 20, 2026.

Does Timothy Schmid report indirect Johnson & Johnson (JNJ) holdings in this Form 4?

Yes. The filing lists 46 shares held indirectly by an ESOP under the Johnson & Johnson Savings Plan and 745 shares held indirectly through a 401(k). These indirect positions are based on the plans’ most recent reporting date of January 31, 2026.

What is Timothy Schmid’s role at Johnson & Johnson (JNJ) in this insider filing?

In this Form 4, Timothy Schmid is identified as an officer of Johnson & Johnson, serving as EVP and Worldwide Chair, MedTech. His executive position makes his equity transactions subject to Section 16 insider reporting requirements under U.S. securities regulations.

How many Johnson & Johnson (JNJ) shares did Timothy Schmid sell in this transaction?

The Form 4 reports that Timothy Schmid sold 1,322 shares of Johnson & Johnson common stock. This was categorized as an open-market or private sale, coded as a “S” transaction, on February 20, 2026, at a reported price of $245.66 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 05:20 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schmid Timothy

(Last) (First) (Middle)

ONE JOHNSON & JOHNSON PLAZA

(Street)

NEW BRUNSWICK NJ 08933

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, WW Chair, MedTech

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		S		1,322	D	$245.66	25,447	D
Common Stock								46(1)	I	By ESOP
Common Stock								745(2)	I	By 401k

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026).

2. Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026).

Remarks:

	/s/ Joleen Morgan, as attorney-in-fact for Timothy Schmid	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.